Log in to save to my catalogue

Immunogenicity Associated with Botulinum Toxin Treatment

Immunogenicity Associated with Botulinum Toxin Treatment

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3a43e248f83747919eeb540bcd10f4f4

Immunogenicity Associated with Botulinum Toxin Treatment

About this item

Full title

Immunogenicity Associated with Botulinum Toxin Treatment

Publisher

Switzerland: MDPI AG

Journal title

Toxins, 2019-08, Vol.11 (9), p.491

Language

English

Formats

Publication information

Publisher

Switzerland: MDPI AG

More information

Scope and Contents

Contents

Botulinum toxin (BoNT) has been used for the treatment of a variety of neurologic, medical and cosmetic conditions. Two serotypes, type A (BoNT-A) and type B (BoNT-B), are currently in clinical use. While considered safe and effective, their use has been rarely complicated by the development of antibodies that reduce or negate their therapeutic eff...

Alternative Titles

Full title

Immunogenicity Associated with Botulinum Toxin Treatment

Authors, Artists and Contributors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_3a43e248f83747919eeb540bcd10f4f4

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3a43e248f83747919eeb540bcd10f4f4

Other Identifiers

ISSN

2072-6651

E-ISSN

2072-6651

DOI

10.3390/toxins11090491

How to access this item